Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable tech...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
National Academy of Sciences
2018
|
| _version_ | 1797096705477312512 |
|---|---|
| author | Micoli, F Rondini, S Alfini, R Lanzilao, L Necchi, F Negrea, A Rossi, O Brandt, C Clare, S Mastroeni, P Rappuoli, R Saul, A Maclennan, C |
| author_facet | Micoli, F Rondini, S Alfini, R Lanzilao, L Necchi, F Negrea, A Rossi, O Brandt, C Clare, S Mastroeni, P Rappuoli, R Saul, A Maclennan, C |
| author_sort | Micoli, F |
| collection | OXFORD |
| description | Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Here we compare equivalent Generalized Modules for Membrane Antigens (GMMA) outer membrane vesicles and O-antigen-CRM197 glycoconjugates to deliver lipopolysaccharide O-antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines. Salmonella strains were chosen and tolR deleted to induce GMMA production. O-antigens were extracted from wild-type bacteria and conjugated to CRM197 Purified GMMA and glycoconjugates were characterized and tested in mice for immunogenicity and ability to reduce Salmonella infection. GMMA and glycoconjugate O-antigen had similar structural characteristics, O-acetylation, and glucosylation levels. Immunization with GMMA induced higher anti-O-antigen IgG than glycoconjugate administered without Alhydrogel adjuvant. With Alhydrogel, antibody levels were similar. GMMA induced a diverse antibody isotype profile with greater serum bactericidal activity than glycoconjugate, which induced almost exclusively IgG1. Immunization reduced bacterial colonization of mice subsequently infected with Salmonella S Typhimurium numbers were lower in tissues of mice vaccinated with GMMA compared with glycoconjugate. S. Enteritidis burden in the tissues was similar in mice immunized with either vaccine. With favorable immunogenicity, low cost, and ability to induce functional antibodies and reduce bacterial burden, GMMA offer a promising strategy for the development of a nontyphoidal Salmonella vaccine compared with established glycoconjugates. GMMA technology is potentially attractive for development of vaccines against other bacteria of global health significance. |
| first_indexed | 2024-03-07T04:45:20Z |
| format | Journal article |
| id | oxford-uuid:d30d0db3-d7b0-49ff-b813-c0a3be32a9f9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:45:20Z |
| publishDate | 2018 |
| publisher | National Academy of Sciences |
| record_format | dspace |
| spelling | oxford-uuid:d30d0db3-d7b0-49ff-b813-c0a3be32a9f92022-03-27T08:08:38ZComparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal SalmonellaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d30d0db3-d7b0-49ff-b813-c0a3be32a9f9EnglishSymplectic Elements at OxfordNational Academy of Sciences2018Micoli, FRondini, SAlfini, RLanzilao, LNecchi, FNegrea, ARossi, OBrandt, CClare, SMastroeni, PRappuoli, RSaul, AMaclennan, CNontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Here we compare equivalent Generalized Modules for Membrane Antigens (GMMA) outer membrane vesicles and O-antigen-CRM197 glycoconjugates to deliver lipopolysaccharide O-antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines. Salmonella strains were chosen and tolR deleted to induce GMMA production. O-antigens were extracted from wild-type bacteria and conjugated to CRM197 Purified GMMA and glycoconjugates were characterized and tested in mice for immunogenicity and ability to reduce Salmonella infection. GMMA and glycoconjugate O-antigen had similar structural characteristics, O-acetylation, and glucosylation levels. Immunization with GMMA induced higher anti-O-antigen IgG than glycoconjugate administered without Alhydrogel adjuvant. With Alhydrogel, antibody levels were similar. GMMA induced a diverse antibody isotype profile with greater serum bactericidal activity than glycoconjugate, which induced almost exclusively IgG1. Immunization reduced bacterial colonization of mice subsequently infected with Salmonella S Typhimurium numbers were lower in tissues of mice vaccinated with GMMA compared with glycoconjugate. S. Enteritidis burden in the tissues was similar in mice immunized with either vaccine. With favorable immunogenicity, low cost, and ability to induce functional antibodies and reduce bacterial burden, GMMA offer a promising strategy for the development of a nontyphoidal Salmonella vaccine compared with established glycoconjugates. GMMA technology is potentially attractive for development of vaccines against other bacteria of global health significance. |
| spellingShingle | Micoli, F Rondini, S Alfini, R Lanzilao, L Necchi, F Negrea, A Rossi, O Brandt, C Clare, S Mastroeni, P Rappuoli, R Saul, A Maclennan, C Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
| title | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
| title_full | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
| title_fullStr | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
| title_full_unstemmed | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
| title_short | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
| title_sort | comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal salmonella |
| work_keys_str_mv | AT micolif comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT rondinis comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT alfinir comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT lanzilaol comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT necchif comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT negreaa comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT rossio comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT brandtc comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT clares comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT mastroenip comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT rappuolir comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT saula comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT maclennanc comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella |